Tandem Labs
We will present four talks and provide a complimentary lunch. The first presentation is at 9:00 AM; pre-event registration by September 22 is encouraged. Registration is by courtesy of Phenomenex and Tandem Labs, and is limited to the first 100 attendees. Stay for the entire day or just for the topic that interests you the most. Visit here to register for this event.
AGENDA and PRESENTERS
9:00 to 9:50 am - Quantitative Determination of Oligonucleotides in Biological Matrix Using LC-MS/MS and UPLC-PDA
Laixin Wang, Ph.D., Method Development Group Leader, Tandem Labs, Salt Lake City, Utah
Dr. Wang is a Group Leader at Tandem Labs, directing method development, method validation and sample analysis of pre-clinical dose formulations, discovery bioanalytical projects, and GLP bioanalysis of large-molecule drugs. His expertise includes the synthesis, formulation, and bioanalysis of oligonucleotide and peptide therapeutics.
After receiving a Ph.D. in medicinal chemistry at Beijing Medical University in 1992 with a thesis on the synthesis of modified oligonucleotides as anticancer agents, Dr. Wang focused on the delivery/formulation of antisense and ribozyme oligonucleotide drugs at the University of Utah, and developed a new method for the synthesis of oligonucleotide arrays (DNA chips) at Duke University. From 2000 until joining Tandem Labs in 2004, he managed the synthesis, formulation, and evaluation of new delivery vehicles for oligonucleotide and hydrophobic drugs at Genta, Inc. (previously Salus Therapeutics).
10:00 to 10:50 am - Recent Developments in Oligonucleotide Isolation and Chromatography
Michael McGinley, Bioseparations Product Manager, Phenomenex, Inc., Torrance, California
Michael McGinley is Bioseparations Product Manager at Phenomenex, managing technical aspects of Phenomenex’s HPLC and bioseparation product portfolios. A recognized chromatography resource and a longtime member of the editorial advisory board of LC/GC magazine, his expertise includes HPLC method development, proteomics, biofuel analysis, oligonucleotide chemistry, protein characterization, and protein purification with over a hundred publications in these fields.
Prior to joining Phenomenex in 2002, Michael held various positions at Amgen for over 12 years, concluding as Laboratory Head. He established and managed the protein core laboratory at the Amgen Colorado inflammatory disease research site, and was a lead scientist in the formation of Amgen’s innovative proteomics program.
11:00 to 11:50 am - Peptide and Protein Analysis
Lily Li, Ph.D., Laboratory Director, Discovery Services, Tandem Labs, Woburn, Massachusetts
Dr. Li is the Laboratory Director at Tandem Labs in Woburn, MA with over 20 years experience in small and large molecule analysis. She built metabolomics and proteomics platforms at PharmaKD. She was a founding scientist and set-up a CLIA laboratory at Cantata Pharmaceuticals. At Monsanto, she led high-throughput analytics to support company-wide genomics and biotech research projects. At ArQule, she was a group leader for HT chemical library screening and lead optimization. She was responsible for GLP method development and validation at Advion BioSciences. With a Ph.D. in food chemistry (Cornell University), and an M.S. in nutritional biochemistry (Univ. of Illinois, Urbana-Champaign), Dr. Li was an NIH post-doctoral fellow in drug testing and toxicology.
12 noon - Lunch at Chauncey Conference Center
1:00 to 1:50 pm - High-throughput Method Development for Bioanalysis
KC Van Horne, Director, Process Innovation and Automation, Tandem Labs, Salt Lake City, Utah
KC Van Horne is Director of Process Innovation and Automation for Tandem Labs, and has over 30 years experience in sample preparation and separation sciences. Duties involve evaluation and oversight of productivity-driven process changes in technology, business, and other operational processes. He developed Tandem’s approach to rapid bioanalytical method development, standardized Tandem’s analytical platforms to achieve company-wide utility/flexibility for various analytical methods, and implemented Symbiosis, a fully-automated platform for on-line solid phase extraction of samples prior to bioanalysis.
He was a primary contributor in discovering matrix effects due to endogenous phospholipids in biological samples, a now widely-acknowledged component of method ruggedness for bioanalytical LC-MS/MS methods. Ongoing projects include full automation of Tandem’s Biotechnology Services Division, implementing rapid, in-silico method development using intelligent databases and predictive chemistry, and investigation of dried blood spot (DBS) technology for sample collection, storage, and subsequent bioanalysis.
Search